Telehealth, ADHD, and the Rich Patient Bonus
2026-07-24
Telehealth did not just widen access; it rewired the incentive grid for ADHD drugs. When Medicare made telepsychiatry reimbursement permanent, a stable revenue stream snapped into place for platforms built around brief, high-yield visits and repeat scripts for stimulants.
The winners are not the most impaired patients. They are the ones with fast broadband, flexible work, and solid insurance, who can book short virtual consults, clear diagnostic thresholds for attention deficit hyperactivity disorder, and lock in monthly renewals. That pattern fits classic moral hazard theory and fee‑for‑service economics, where each fifteen‑minute encounter becomes a billable unit and medication management outcompetes labor‑intensive psychotherapy.
Telepsychiatry startups have learned to leverage that structure. They optimize intake funnels, automate symptom checklists, and integrate electronic prescribing, turning clinical workflows into a closed-loop business system that rewards volume. Stimulant scripts become the moat: once a patient depends on a controlled substance, churn drops and lifetime value rises, especially in commercially insured populations.
Left on the margins are poorer patients, often with unstable housing, patchy internet, or public coverage that reimburses at lower rates and restricts brand‑name drugs. For them, the promise of remote care is blunted by prior authorization rules, shortage of child psychiatrists, and limited capacity for detailed neurocognitive assessment, including standardized rating scales and longitudinal functional evaluation.
Telehealth psychiatry now sits at an awkward frontier, where a tool designed to shrink distance instead widens the gap between those who can monetize their symptoms and those who simply live with them.
Loading...
